IMAGEENS
IMAGEENS, a Paris-based medical Artificial Intelligence (AI) startup developing software solutions for the analysis of medical images, has secured 1.2Mn€ in seed financing. The round was led by Anaxago, with a participation from BADGE (Business Angels des Grandes Ecoles), COALESCENCE, and existing IMAGEENS investors.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210415005466/en/
IMAGEENS' software solutions allow radiologists, cardiologists and vascular surgeons to make personalized decisions and to better assess the cardiovascular risk of their patients, thanks to highly accurate medical imaging data.
The funding will allow IMAGEENS to accelerate the development and commercialization of ArtFun+, an artificial intelligence software and its prognostic biomarkers for cardiovascular imaging, and LABEL, an algorithmic solution for the automatic classification and valorization of medical imaging data. It will also allow to strengthen its team with key R&D talents and build its commercial team to scale the deployment of its software solutions.
"We are delighted to have been able to quickly complete this round table in collaboration with ANAXAGO. We will be able to announce the launch of several strategic projects as well as key hires in the coming months, which will be the cornerstones of IMAGEENS' development over the next few years," said Robert Baldwin, CEO of IMAGEENS .
ArtFun+ stems from the US National Institute of Health (NIH)-funded Multi-Ethnic Study of Atherosclerosis (MESA) which studied the prognostic power of imaging biomarkers on a multi-ethnic cohort of 3675 patients across the United States. In the study, the imaging biomarkers of ArtFun+ were shown to be highly predictive of death and hard cardiovascular for patients between 45 and 84 years old. Beyond the MESA trial, the imaging biomarkers of ArtFun+ were studied in 77 scientific publications and used in 31 leading clinical centers around the globe.
Today, IMAGEENS is in the process of obtaining FDA and CE-clearance for ArtFun+ in routine cardiovascular care to complement to cardiac MRI exams with cardiovascular risk biomarkers enabling improved follow-up and surgical decisions in ischemic cardiopathies, acute coronary syndrome, and aortic aneurysms.
Since late 2020, IMAGEENS has also developed a complementary business to its diagnostic solutions, by helping Europe’s largest medical data warehouses improve the quality of their medical data and use it for R&D and AI-training purposes. By working with leading medical institutions such as the AP-HP in Paris, IMAGEENS has developed a comprehensive set of image classification algorithms that automatically create metadata allowing the data warehouses to get a detailed understanding of the databases’ content, and the ability to precisely query the medical data to setup cohorts for R&D and AI-training projects.
ABOUT IMAGEENS
Founded in 2017, IMAGEENS develops software solutions for doctors to leverage the full potential of advanced medical imaging data. IMAGEENS commercializes two products: ArtFun+, an innovative software to calculate vascular stiffness and flow imaging biomarkers that are predictive of patients’ long-term risk of death and hard cardiovascular events, and LABEL, a set of image classification algorithms that enable large medical data warehouses to precisely query and create data cohorts for R&D and AI-training projects.
ABOUT ANAXAGO
Created in 2012, the Anaxago group is the first 100% digital private neo-bank, accessible to the greatest number of people, combining impact and performance. With more than 100,000 members, 250 companies and real estate projects financed since its creation and more than 250 million euros collected, Anaxago stands out for the selectivity and the support of the investment projects proposed on its platform. Anaxago is an independent group, majority owned by its founders, and currently has 40 employees. The investment in IMAGEENS was led by Alex Heraud and Gaston Vasseur. Anaxago counsels: M Guilain Hippolyte, Reed Smith LLP.
www.anaxago.com
ABOUT BADGE
Created in 2004 Les Business Angels des Grandes Ecoles is one of the largest networks of Business Angels in France. The mission is to support the development of emerging innovative projects with high growth potential. Since 2005 BADGE has financed 188 projects with 38 M€, having generated a total financing of more than 100 M€.
www.business-angels.info
ABOUT COALESCENCE
Coalescence is a network of Business Angels sharing the same values; they wish to promote the growth of young innovative projects. Beyond finance the members of Coalescence bring kind support with their various professional background.
www.coalescence.fr
View source version on businesswire.com: https://www.businesswire.com/news/home/20210415005466/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
KRAFTON Achieves Record-High Quarterly Sales in Q1 202529.4.2025 09:00:00 CEST | Press release
Thanks to PUBG IP expansion, inZOI’s strong debut, and BGMI’s global growth, quarter-over-quarter sales are up 41.6%, while operating profit is up 112.2% KRAFTON, Inc. today announced its first quarter earnings results for 2025. Based on consolidated financial statements prepared in accordance with Korean International Financial Reporting Standards (K-IFRS), the company achieved a record-high quarterly sales performance of 874.2B KRW and operating profit of 457.3B KRW. In addition to high quarter-over-quarter growth, year-over-year growth has also set records with sales up by 31.3% and operating profit upby 47.3%. Significant Growth and Core IP Direction KRAFTON achieved significant growth across all of its business divisions, including PC (323.5B KRW), mobile (532.4B KRW), and console/others (18.3B KRW). On PC platforms, PUBG: BATTLEGROUNDS’ diversified content and strong live-service operations contributed significantly to growth while the successful launch of a new IP, inZOI, also p
Azalea Vision Raises €9 Million in First Closing of Series A to Further Develop Intelligent Connected Vision Platform29.4.2025 09:00:00 CEST | Press release
Industry veteran Robert J. Dempsey Appointed Chairman of the Board to Guide Strategic Growth in Europe and the U.S. Azalea (A-zuh-lay-ah)Vision, a HealthTech company engineering the future of sight, today announced the first closing of its €15 million Series A funding round, raising €9 million along with the appointment of Robert J. Dempsey as Chairman of the Board to guide strategic growth in the European and U.S. markets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250429247873/en/ Robert Dempsey, Chairman of the Board, Azalea Vision "Strong participation from repeat investors in this Series A milestone reaffirms their trust in our medical device and innovation for the future of intelligent ocular health,” said Enrique Vega, CEO of Azalea Vision. “Additional funding in this round from SPRIM Global Investments and Afrimobility, along with a strategic investor who remains undisclosed, further emphasizes the confidence in
A Third of Global CIOs Warn of Unrealistic Board Expectations as The World Bets Big on AI, According to Expereo29.4.2025 09:00:00 CEST | Press release
A new survey commissioned by Expereo exposes the true roadblocks to global AI plans - poor infrastructure, resistance from employees, unreasonable demands A third of global technology leaders believe their board has unrealistic expectations or demands on how new technologies like AI will impact business performance. This is according to an IDC InfoBrief*, commissioned by Expereo, which highlights serious roadblocks to global AI implementation, despite AI being considered critical to fulfilling business priorities. The research of 650 technology leaders in global organizations across Europe, the US and APAC reveals that 34% of global technology leaders have been forced to reassess their technology infrastructure because of rising geopolitical risks, as 37% say geopolitical disruptions are currently impacting their organization’s growth strategies. Amid the volatile economic backdrop, it seems most organizations are placing their bets on AI to drive growth. The research shows that 87% of
Cyber Guru Named Winner of the Coveted Global InfoSec Awards during RSA Conference 202529.4.2025 09:00:00 CEST | Press release
Cyber Guru Wins Hot Company in Security Awareness Training in the 13th Annual Global InfoSec Awards at #RSAC 2025 Cyber Guru, the leading cybersecurity awareness training platform, is proud to announce we have won the “Hot Company - Security Awareness Training” award from Cyber Defense Magazine (CDM), the industry’s leading electronic information security magazine. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250429950821/en/ Cyber Guru, Global InfoSec Award Winner 2025 “We’re thrilled to receive one of the most prestigious and coveted cybersecurity awards in the world from Cyber Defense Magazine, during their 13th anniversary as one of the world’s leading independent cybersecurity news and information provider. We knew the competition would be tough and with top judges who are leading infosec experts from around the globe, we couldn’t be more pleased,” said Gianni Baroni, CEO and founder of Cyber Guru. Cyber Guru embodies
Microba Delivers Landmark IBD Results & Signs Major Gastro Partner29.4.2025 07:52:00 CEST | Press release
Two independent clinical studies have demonstrated that Microba’s MetaPanel™ test identifies gastrointestinal pathogens in >35% of Inflammatory Bowel Disease (IBD) patients experiencing flare, with >60% of these missed by current routine testing methods.These findings have the potential to shift treatment protocols and provide a new path to remission for IBD patients, avoiding unnecessary therapy escalation or surgery.Microba partners with Colonoscopy Clinic and Integrated Gut Health, one of Australia’s largest private gastroenterology services, to embed microbial diagnostic testing into routine care to improve patient outcomes. Microba Life Sciences Limited (ASX: MAP) (“Microba”) a precision microbiome company, today announces two significant developments: the release of new clinical utility results for its MetaPanel™ gastrointestinal pathogen test, and the signing of a strategic clinical partnership with the Colonoscopy Clinic, and its wholly owned partner, Integrated Gut Health, one
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom